Dados B3 › VIVT3 × MLAS3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | VIVT3 | MLAS3 | year |
|---|---|---|---|
| ROE | 8.9% | 0.0% | 2025 |
| ROIC | 10.1% | 3.3% | 2025 |
| ROA | 4.9% | 2.3% | 2025 |
| Gross margin | 44.8% | 24.7% | 2025 |
| EBIT margin | 16.5% | 2.7% | 2025 |
| Net margin | 10.4% | 3.1% | 2025 |
| Net debt/EBITDA | 0.53x | -1.03x | 2025 |
| Current ratio | 1.00x | 1.92x | 2025 |
| Revenue growth (1y) | 6.7% | 15.8% | 2025 |
| Revenue growth (5y CAGR) | 6.7% | 6.6% | 2025 |
| Piotroski F-Score | 7/9 | 7/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | VIVT3 | MLAS3 | year |
|---|---|---|---|
| P/E | 21.78x | — | 2025 |
| P/B | 1.95x | 0.37x | 2025 |
| EV/EBITDA | 5.95x | 5.71x | 2025 |
| FCF yield | 8.4% | 6.8% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 13:37 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it